Gebro Pharma's psoriasis drug could be on the market sooner than expected

- Piclidenoson is in phase III clinical trials for rheumatoid arthritis and psoriasis, Gebro Pharma's focus areas.
- The laboratory will be the exclusive distributor of piclidenoson in Spain, Switzerland and Austria upon receipt of regulatory approvals.

Barcelona, 23/11/2020.- Gebro Pharma, a leading company in pain and rheumatology with a strong product portfolio, could accelerate the market launch of a new molecule for the treatment of psoriasis sooner than expected, according to the interim results of a phase III study.

Piclidenoson, the main candidate drug developed by the biotechnology company Can-Fite, has shown positive results in an interim analysis of the ongoing phase III clinical trial in patients with moderate to severe plaque psoriasis, pathology within the focus area of Gebro Pharma. Can Fite and Gebro Pharma signed an exclusive distribution right agreement for the drug in Spain, Switzerland and Austria back in 2018.

An Independent Data Monitoring Committee (IDMC) carried out an interim analysis of the Comfort ™ phase III psoriasis trial designed to establish piclidenoson's superiority compared to placebo and non-inferiority compared to apremilast in patients with moderate to severe plaque psoriasis. The randomized, double-blind study is being conducted in Europe, Israel and Canada. Based on the positive results of the interim analysis, the IDMC has recommended to drop one dose group and to continue the study with the original sample size. This means that an optimal dose has been found and that the study can be concluded earlier than what had been originally planned.

" *We are very pleased with the results obtained to date in the Comfort™ study. Our ultimate goal is to provide a solution for all those patients with psoriasis, and the latest data indicates that this reality will be possible sooner than expected, always ensuring the best levels of quality and safety for the patients*" , said Sergi Aulinas, General Director of Gebro Pharma.

" *While the interim analysis data continues to be blinded to Gebro Pharma and Can Fite, and the results have only been available to the IDMC, their recommendation to continue the Phase III psoriasis study and to drop one of the dosing groups are highly encouraging. There is a real market need for an efficacious and safe oral drug for this devastating disease. We thank the members of both of the IDMCs for their diligence in reviewing our Phase III interim data and for making their recommendations"* stated Can-Fite CEO Dr. Pnina Fishman.

Piclidenoson offers several potential key benefits over psoriasis treatments currently on the market. As an oral pill taken twice daily, it offers an easy administration for patients who tend to prefer oral medications over injectables. Moreover, piclidenoson has been dosed in over 1,500 patients with an excellent safety profile in clinical trials to date.. While psoriasis is a serious disease with quality of life implications for patients, it is not life threatening and therefore patients recognize that while they need an effective treatment, safety is also a very high priority.

About Can Fite

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, inflammatory disease and COVID-19. The Company's lead drug candidate, Piclidenoson, is currently in Phase III trials for rheumatoid arthritis and psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and successfully achieved its primary endpoint in a Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,500 patients in clinical studies to date. For more information please visit: www.can-fite.com.

About Laboratorios Gebro Pharma

Laboratorios Gebro Pharma is a pharmaceutical company dedicated to the development and marketing of prescription and hospital drugs. Present in Spain since 2002 and based in Barcelona, the company currently has 165 employees in its country. It is part of the Austrian pharmaceutical group Gebro Pharma GmbH which, for more than 70 years, has been working in the research, manufacture and marketing of pharmaceutical specialties.

In Spain, the company is a benchmark and develops and markets a portfolio of benchmark drugs in the areas of pain, rheumatology -its main area of knowledge-, urology, respiratory and dermatology.

www.gebro.es

For more information, please contact:
GEBRO PHARMA
Telf: + 34 93 205 86 86
laboratorios@gebro.es

ATREVIA
Marta Marinero
Telf. +34 667 631 733
mmarinero@atrevia.com

ATREVIA
Laura Casals
Telf. +34 667 631 827
lcasals@atrevia.com